Sana Biotechnology, Inc.

Sana Biotechnology, Inc. develops engineered cells to treat diseases. The company focuses on two main approaches: ex vivo and in vivo cell engineering platforms. Its ex vivo platform utilizes a hypoimmune platform technology, referred to as HIP technology. This technology aims to engineer allogeneic cells that can evade a patient's immune system, preventing rejection and allowing the cells to persist in the body, while also being manufacturable at scale. The company believes this approach can lead to new therapeutics, starting with type 1 diabetes. SC451 is Sana Biotechnology, Inc.'s HIP-edited product candidate for treating type 1 diabetes. For in vivo therapies, the company focuses on cell-specific delivery of genetic payloads, specifically chimeric antigen receptors (CARs), to a patient's T cells. This process generates and proliferates CAR T cells, which are designed to deplete disease-causing B cells. SG293 is Sana Biotechnology, Inc.'s in vivo CAR T product candidate, currently being advanced for the treatment of B cell malignancies and B cell mediated autoimmune diseases. Sana Biotechnology, Inc. aims to address unmet treatment needs across various therapeutic areas, including type 1 diabetes, oncology, and B cell mediated autoimmune diseases.